Efficacy and safety of fuzuloparib combined with bevacizumab as maintenance treatment for PARP inhibitor-pretreated platinum-sensitive recurrent ovarian cancer: a phase II study

International Journal of Gynecological Cancer 2026

View at publisher

Authors: Dongling Zou, Lin Zhong, An Lin, Liang Chen, Qingshui Li, Yingmei Wang, Huijuan Yang, Lei Li, Tao Zhu

DOI: 10.1016/j.ijgc.2025.104425

Cited by: 0

Fields of Study & Subjects

PARP inhibition in cancer therapy Ovarian cancer diagnosis and treatment BRCA gene mutations in cancer